4,5,6,7-四氢-1,2-苯并噻唑 | 60230-92-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 4,5,6,7-四氢-1,2-苯并噻唑
• 英文名称: 4,5,6,7-Tetrahydro-1,2-benzothiazol
• 英文别名: 4,5,6,7-tetrahydro-benzo[d]isothiazole；InChI=1/C7H9NS/c1-2-4-7-6(3-1)5-8-9-7/h5H,1-4H；4,5,6,7-tetrahydro-1,2-benzothiazole
• CAS: 60230-92-4
• 化学式: C₇H₉NS
• 分子量: 139.221
• InChiKey: RGYKQAJMNWWHLA-UHFFFAOYSA-N

物化性质

• 沸点：
  97 °C(Press: 6 Torr)
• 密度：
  1.170±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,5,6,7-四氢-1,2-苯并噻唑 在 双氧水 作用下， 以 溶剂黄146 为溶剂， 反应 0.33h， 以60%的产率得到4,5,6,7-四氢-1,2-苯并异噻唑-3(2H)-酮 1,1-二氧化物
  参考文献：
  名称：

  Zur Oxidation von 1,2-Thiazolen：Ein einfacher Zugang zu 1,2-Thiazol-3（2 H）-on-1,1-dioxiden †

  摘要：

  1,2-噻唑的氧化; 1,2-Thiazol-3（2 H）-one 1,1-Dioxides的简便方法

  DOI：

  10.1002/hlca.19910740515
• 作为产物：
  描述：

  2-thiocyanato-cyclohex-1-enecarbaldehyde 在 硫氰酸铵 作用下， 以 丙酮 为溶剂， 反应 1.0h， 生成 4,5,6,7-四氢-1,2-苯并噻唑
  参考文献：
  名称：

  Muehlstaedt,M. et al., Journal fur praktische Chemie (Leipzig 1954), 1976, vol. 318, p. 507 - 514

  摘要：

  DOI：

文献信息

• Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150307465A1

  公开（公告）日：2015-10-29

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

  本发明提供了多种形式的亚氨基噻二唑二氧化物化合物，包括公式(I)的化合物： 包括它们的立体异构体，以及所述立体异构体的药用可接受盐，其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-都是独立选择且按本文定义。发明的新型亚氨基噻二唑二氧化物化合物出人意料地被发现具有预期的特性，使其作为BACE抑制剂以及/或用于治疗和预防与β-淀粉样蛋白（“Aβ”）生成相关的各种病理学具有优势。还公开了包含一个或多个此类化合物（单独使用和与一个或多个其他活性成分组合使用）的药物组合物，以及它们的制备方法和用于治疗与淀粉样β（Aβ）蛋白相关的病理学，包括阿尔茨海默病的方法。
• [EN] PYRROLIDINE-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE<br/>[FR] COMPOSÉS DE DIOXYDE DE THIADIAZINE FUSIONNÉE À LA PYRROLIDINE EN TANT QU'INHIBITEURS DE BACE, COMPOSITIONS ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2012138590A1

  公开（公告）日：2012-10-11

  In its many embodiments, the present invention provides provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein each of W, Z, R1H, R2, R3, R4, ring A, ring B, m, n, p, and- L1- is as defined herein. The novel compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer's disease, are also disclosed.

  在其众多实施方式中，本发明提供了特定的咪唑噻二唑二氧化物化合物，包括化合物式（I）中的化合物及其互变异构体和立体异构体，以及所述化合物的药用可接受盐，所述互变异构体和所述立体异构体，其中W、Z、R1H、R2、R3、R4、环A、环B、m、n、p和-L1-的每一个在此处定义。本发明的新化合物被发现具有出乎意料的性质，预计将使它们在作为BACE抑制剂和/或用于治疗和预防与之相关的各种病理方面具有优势。还公开了包括一种或多种此类化合物（单独或与一种或多种其他活性剂的组合）的制备和使用方法，包括治疗阿尔茨海默病的药物组合。
• [EN] IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE<br/>[FR] COMPOSÉS DE TYPE DIOXYDE D'IMINO-THIADIAZINE UTILISÉS EN TANT QU'INHIBITEURS DE BACE, COMPOSITIONS EN CONTENANT ET LEUR UTILISATION
  申请人：SCHERING CORP

  公开号：WO2011044187A1

  公开（公告）日：2011-04-14

  In its many embodiments, the present invention provides provides certain iminothiadiazine dioxide compounds, including compounds Formula (a) and include tautomers, solvates, prodrugs, esters, and deuterates thereof, and pharmaceutically acceptable salts of said compounds, tautomers, solvates, prodrugs, esters, and deuterates, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, ring C, m, n, p, q, -L1-, -L2-,L3-, and L4- is selected independently and as defined herein. The compounds of the invention have, surprisingly and advantageously, improved solution stability. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers Disease, are also disclosed.

  在其多种实施方式中，本发明提供了某些咪唑二氧化硫化合物，包括化合物的结构式(a)以及其互变异构体、溶剂合物、前药、酯类和氘代物，以及所述化合物、互变异构体、溶剂合物、前药、酯类和氘代物的药用可接受盐，其中R1、R2、R3、R4、R5、R9、环A、环B、环C、m、n、p、q、-L1-、-L2-、L3-和L4-中的每一个都是独立选择并在此定义。本发明的化合物具有出乎意料且有利的改善溶液稳定性。还披露了包含一个或多个这种化合物的药物组合物（单独和与一个或多个其他活性剂的组合），以及其制备和用于治疗与淀粉样蛋白β（Aβ）蛋白相关的病理的方法，包括阿尔茨海默病。
• PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS AND THEIR USE
  申请人：Iserloh Ulrich

  公开号：US20120195881A1

  公开（公告）日：2012-08-02

  In its many embodiments, the present invention provides certain pentafluorosulfur imino heterocyclic compounds, including compounds Formula (a) and pharmaceutically acceptable salts thereof. Compounds of Formula (a) have the general structure: (a) wherein each variable is selected independently and as defined herein. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers Disease, are also disclosed.

  在它的许多实施例中，本发明提供了特定的五氟硫酰亚胺杂环化合物，包括式（a）的化合物及其药学上可接受的盐。式（a）的化合物具有以下一般结构：（a），其中每个变量是独立选择且如此定义的。本发明还揭示了包含一个或多个此类化合物（单独和与一个或多个其他活性剂的组合）的制药组合物，并用于治疗与淀粉样β（Aβ）蛋白相关的病理状况，包括阿尔茨海默病的方法。
• [EN] IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE<br/>[FR] COMPOSÉS DE DIOXYDE D'IMINOTHIADIAZINE COMME INHIBITEURS DE BACE, COMPOSITIONS ET LEUR UTILISATION
  申请人：SCHERING CORP

  公开号：WO2011044181A1

  公开（公告）日：2011-04-14

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, m, n, p, -L1-,L2-, and L3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (Aβ) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers disease, are also disclosed.

  在其多种实施方式中，本发明提供了某些亚氨基噻二嗪二氧化物化合物，包括化合物式(I)的化合物和其立体异构体，以及所述化合物立体异构体的药学上可接受的盐，其中每个R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、L2-和L3-都是独立选择并在此定义。该发明的新型亚氨基噻二嗪二氧化物化合物出人意料地表现出具有优势的BACE抑制剂特性和/或用于治疗和预防与β-淀粉样蛋白（Aβ）产生相关的各种病理的特性。还公开了包括一种或多种这样的化合物（单独和与一种或多种其他活性剂的组合）的制药组合物，并揭示了在治疗与淀粉样β（Aβ）蛋白相关的病理，包括阿尔茨海默病中使用它们的方法。

表征谱图